About Aditi Ganguly
Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities.
Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis. After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww. Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.
Recent Articles By Aditi Ganguly
Why CarGurus Stock is a Better Investment Than CarMax
As the largest used-car retailer in the United States, CarMax (KMX) has dominated the second-hand automotive market for a long time. However, online marketplace platform CarGurus (CARG) has an impressive growth history and financial strength, with, we think, the potential to outperform KMX soon. Read on to learn more.
Is Agree Realty Over or Undervalued?
Retail REIT stock Agree Realty (ADC) has been surging because outdoor activities and consumer spending are expected to rise. However, with people having become comfortable with their remote lifestyles over the last year, will the retail REIT be able to grow its revenues enough to justify its valuation? Read more to find out.
Is Rapid7 a Good Cybersecurity Stock to Add to Your Portfolio?
Rapid7 (RPD) has been surging over the past year on investor optimism regarding the cybersecurity industry. However, because the anticipated economic recovery has led to an embrace of a fundamental approach to investing, RPD’s premium valuation and significant debt have made investors lose confidence in the stock. So, will RPD be able to repair its market image to regain its lost momentum? Read more to find out.
Is New Residential Investment a Good REIT to Own?
Shares of New Residential Investment (NRZ) have gained in double digits over the past year as the housing market hit multi-year highs. However, the recent rise in Treasury bond yields has raised expectations regarding a potential rise in benchmark interest rates. This would increase the interest expense burden on NRZ. So, will NRZ be able to maintain its growth trajectory? Read more to find out.
Should Investors Buy Science Applications International Stock?
The stock of Science Applications International (SAIC), which provides IT services to top government agencies in the United States, has been declining due to a renewed focus by investors on turnaround non-tech stocks. So, will SAIC be able to regain its momentum as governments sharpen their focus on highly secure IT operators following notorious cyberattacks last year? Read on to find out.
Medallia: Buy, Sell, or Hold?
After reporting double-digit gains over the past year, the shares of software developer Medallia (MDLA) are currently on a downtrend. Given the company’s weak financial outlook and unfavorable analyst sentiment, we think investors should sell the stock now.
Up 125% in the Past Year, is VICI Properties Still a Buy?
A high dividend yield and brand recognition helped VICI Properties (VICI) retain its momentum amid the economic ravages of the COVID-19 pandemic despite the slump experienced by commercial REITs. However, as the industry recovers rapidly, will VICI be able to solve its surging debt problem? Read more to find out.
Should You Buy the Dip in Shares of RingCentral?
Cloud communications provider RingCentral (RNG) has been declining recently as part of a tech sell-off by investors who are now focusing on stocks with the potential to turnaround with an economic recovery—a recovery that is being fueled by fiscal stimulus checks and mass coronavirus vaccination programs. So, will RNG, which was surging due primarily to the pandemic-driven tech boom, be able to deliver stable returns post pandemic? Read more to find out.
Here is Why Investors Should Buy Qiagen N.V. Now
The molecular diagnostics company Qiagen (QGEN) has been declining over the past couple of months because an expected economic recovery is steering investors’ attention toward turnaround stocks. So, will the company’s COVID-specific products and varied sequencing technologies allow the stock to regain its momentum? Read more to find out.